CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
PRESIST-SEQ aims to establish a new standard in single-cell experimental workflows for cancer research. By developing best practices and high-quality data, the project seeks to help researchers identify markers for predicting and targeting therapeutic resistance in tumors, ultimately improving treatment strategies.
It is the ambition of PRESIST-SEQ to provide a new gold standard in single-cell experimental workflows the cancer research community by developing best practices, standard operating procedures (SOPs), and high-quality FAIR data, with the ultimate aim to empower them to unravel therapeutic resistance.
Such, that the community can identify urgently needed markers to predict, prevent, and target tumour resistance.
Cancer takes 9.6 million lives each year, 90% of which result from untreatable metast…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Netherlands, UTRECHT
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
